Trial Profile

Phase I/II of Venetoclax in Combination With Azacitidine in Treatment Naïve and Relapse Refractory High Risk MDS Individuals

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Adverse reactions

Most Recent Events

29 May 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
29 May 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
12 Dec 2023 Results of pooled analysis from NCT04160052, NCT04550442,NCT04655755 ,explaining resistance of GMP pattern and MDS to venetoclax therapy presented at the 65th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com